Quan Anh Vu bought MNPR once, on Dec 26, 2025

Quan Anh Vu is the Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer of Monopar Therapeutics Inc. (NASDAQ: MNPR), a clinical-stage biopharmaceutical company focused on oncology and rare diseases. Appointed to these roles effective March 3, 2025, succeeding Karthik Radhakrishnan, Vu brings over 20 years of experience in corporate finance, financial strategy, investment banking, and public company leadership within the healthcare sector.

Vu's career highlights include serving as CFO and Chief Business Officer at Ocugen, Inc. (NASDAQ: OCGN) in 2023, and COO and Chief Business Officer at 180 Life Sciences Corp. (NASDAQ: ATNF) from November 2021 to January 2023. He previously held the role of Vice President and Head of Strategy and Corporate & Business Development at Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) from September 2016 to August 2019, until its acquisition by Indivior PLC. Earlier positions encompass leadership roles at Impax Laboratories, Inc., Elevance Health, Inc. (formerly Anthem, Inc.), and Amgen, Inc. (NASDAQ: AMGN), complemented by early-career stints in healthcare corporate finance and M&A at Morgan Stanley and Goldman Sachs. Most recently, from October 2024 to February 2025, he was a Venture Partner at ZhongMei Capital, and he has provided consulting services via Melius BioPharma Consulting.

Vu holds an MS in Legal Studies from Cornell University Law School and a BA in Economics from UCLA, earned summa cum laude with College and Economics Departmental Honors. He is a Certified Treasury Professional (inactive). As part of his Monopar compensation, he receives an annual base salary of $350,000, a target bonus up to 35% of base salary, and stock options for 25,000 shares.

Written by Perplexity from public sources.